← FDA DRUG APPROVALS

FDA ANDA · ANDA212917

NEBIVOLOL HYDROCHLORIDE

Sponsor: REYOUNG

APPLICATION
ANDA212917
TYPE
ANDA
ORIGINAL APPROVAL
2021-12-17
LATEST ACTION
2021-12-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

NEBIVOLOL HYDROCHLORIDEPrescription
NEBIVOLOL HYDROCHLORIDE EQ 2.5MG BASE · TABLET · ORAL
NEBIVOLOL HYDROCHLORIDEPrescription
NEBIVOLOL HYDROCHLORIDE EQ 20MG BASE · TABLET · ORAL
NEBIVOLOL HYDROCHLORIDEPrescription
NEBIVOLOL HYDROCHLORIDE EQ 5MG BASE · TABLET · ORAL
NEBIVOLOL HYDROCHLORIDEPrescription
NEBIVOLOL HYDROCHLORIDE EQ 10MG BASE · TABLET · ORAL

Approval history

2021-12-17UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →